Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01161498 · ClinicalTrials.gov registry record · Phase 3
Study of Safety and Efficacy of Talimogene Laherparepvec With Cisplatin and Radiotherapy for Treatment of Locally Advanced Head and Neck Cancer
A Phase 3 study, sponsored by BioVex Limited.
- Terminated
- Registry status
- Phase 3
- Development phase
- 5
- Enrollment target
NCT01161498 is a Phase 3 study that was terminated before completion, run by BioVex Limited. The registered enrollment target is 5 participants.
The verdict
NCT01161498, a Phase 3 study, was terminated before completion, sponsored by BioVex Limited.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 5 participants
- Enrollment target
Study Summary
This study is being conducted to learn about the safety and risks of using talimogene laherparepvec to treat patients with head and neck cancer and to see if talimogene laherparepvec and chemoradiation together can destroy the tumours versus the use of chemoradiation alone. This study may provide information on the usefulness of talimogene laherparepvec combined with chemoradiation as a future treatment for head and neck cancer.
Interventions
- DRUG Cisplatin
- RADIATION Radiation
- BIOLOGICAL Talimogene Laherparepvec
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2011-02 |
| Est. Completion | 2011-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01161498
The ClinicalTrials.gov registry entry for NCT01161498 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BioVex Limited, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cisplatin is the first listed.
NCT01161498 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01161498 about?
NCT01161498 is a clinical study titled "Study of Safety and Efficacy of Talimogene Laherparepvec With Cisplatin and Radiotherapy for Treatment of Locally Advanced Head and Neck Cancer". This study is being conducted to learn about the safety and risks of using talimogene laherparepvec to treat patients with head and neck cancer and to see if talimogene laherparepvec and chemoradiation together can destroy the tumours versus the use of chemoradiation alone. This study may provide in...
What is the current status of trial NCT01161498?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 5 participants. The study started on 2011-02. Estimated completion is 2011-10.
What interventions are being tested in trial NCT01161498?
The interventions under investigation include: Cisplatin (DRUG), Radiation (RADIATION), Talimogene Laherparepvec (BIOLOGICAL).
Who is sponsoring clinical trial NCT01161498?
This trial is sponsored by BioVex Limited, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.